Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

Conditions

• Chronic Kidney Disease

Eligibility Criteria

Sex

ALL

Age

6 Months - 22 Years

Healthy Volunteers

Not accepted

Study Details

The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).

Key Dates

Start date

Oct 31, 2003

Status verified

Apr 2026

Primary completion

Jul 31, 2028

Completion

Jul 31, 2028

Study Design

Enrollment

1,300 participants (estimated)

Arms

• Arm: Cohort 1
  Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min\|1.73m2
• Arm: Cohort 2
  Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min\|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease.
• Arm: Cohort 3
  Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
• Arm: Cohort 4
  Age between 16 and 22 years (before 23rd birthday) with moderately impaired kidney function as defined by estimated GFR less than 60 ml/min\|1.73m2 based on U25eGFR OR individuals who have initiated kidney replacement therapy (dialysis or transplant).

Primary Outcome Measure

Time to Kidney Replacement Therapy [ Time Frame: Annually up to 5 years ]

Central Contacts

• Susan Furth, MD, PhD
  215-590-2449
  [email protected]
• Bradley Warady, MD
  816-302-3010
  [email protected]

Locations (2)

Find similar trials in Kansas City, MO

Related Studies

• Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
  Recruiting · University of Michigan · Ann Arbor, Michigan
• A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
  PHASE3 · Recruiting · Amgen · Los Angeles, California
• A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
  PHASE3 · Recruiting · Bayer · Phoenix, Arizona
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  PHASE3 · Recruiting · Bayer · Phoenix, Arizona